Amprion and Modality.AI have formed a collaboration to explore the combined use of molecular biomarkers and artificial ...

Roche (ROG: SIX) has discontinued two Huntington’s disease programs, ending the long-running development of tominersen after ...

GSK (LSE: GSK) has terminated its neurodegeneration collaboration with Alector (Nasdaq: ALEC), ending an alliance established ...

A clinical-stage biopharmaceutical company pioneering immunometabolism-based therapies to treat chronic autoimmune and inflammatory diseases through oral small molecules that modulate immune cell ...

Headquartered in Antwerp, Belgium, with an additional site in Denmark (Aarhus). The company is developing macrophage-targeted therapies intended for patients globally, and operates within the ...

Israeli drugmaker Teva Pharmaceutical Industries has expanded its biosimilars pipeline through a global licensing agreement ...

India's Dr Reddy's Laboratories today revealed that supplies of its generic semaglutide would remain unavailable in India and ...

Anglo-Swedish pharma major AstraZeneca has licensed ex-China rights to TQC3721, an investigational inhaled PDE3/4 inhibitor ...

The US Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for Zoryve (roflumilast) ...

The CARDIO-TTRansform Phase III trial for AstraZeneca (LSE: AZN) and Ionis Pharmaceuticals (Nasdaq: IONS), Wainua (eplontersen) in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) ...

A Massachusetts-based biotechnology company formerly known as Vaxess Technologies, Terrestrial Bio is developing a proprietary microarray patch platform that enables the temperature-stable, ...

South Korean biosimilar specialist Samsung Bioepis today announced that it has entered into a license agreement with Proteina Co to collaborate on a government-supported national R&D initiative aimed ...